FAQ: Soligenix Expands European Medical Advisory Board for HyBryte Phase 3 Study
Summary
Soligenix has expanded its European Medical Advisory Board to guide the confirmatory Phase 3 trial of HyBryte for early-stage cutaneous T-cell lymphoma, with top-line results expected in the second half of 2026. This strategic move strengthens European engagement ahead of potential commercialization of the novel photodynamic therapy.
What is the main announcement from Soligenix?
Soligenix announced the expansion of its European Medical Advisory Board to guide its confirmatory Phase 3 trial of HyBryte in early-stage cutaneous T-cell lymphoma, strengthening European engagement ahead of potential commercialization.
What is HyBryte and what condition does it treat?
HyBryte (SGX301 or synthetic hypericin sodium) is a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease where there is an unmet medical need.
What are the details of the Phase 3 study?
The confirmatory Phase 3 trial is an 18-week study enrolling about 80 patients with early-stage cutaneous T-cell lymphoma, with top-line results expected in the second half of 2026.
Why is this expansion of the European Medical Advisory Board significant?
This expansion strengthens European engagement ahead of potential commercialization and provides expert guidance for the confirmatory Phase 3 trial, positioning the company for global regulatory approvals if the study is successful.
What other development programs does Soligenix have?
Soligenix has multiple development programs including synthetic hypericin expansion into psoriasis, dusquetide for inflammatory diseases, and vaccine programs for ricin toxin, filoviruses, and COVID-19 using their proprietary ThermoVax heat stabilization technology.
Where can investors find the latest news and updates about Soligenix?
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
What is Soligenix’s business focus?
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, with two main business segments: Specialized BioTherapeutics and Public Health Solutions.
How is Soligenix’s Public Health Solutions business segment funded?
The Public Health Solutions business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 239290